A monoclonal antibody 1A6 to T-cell recognizes a common antigen expressed on lymphocytes from normal and leukemic patients, and inhibits NK cell activity.

Abstract:

:A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that this antibody reacts with normal human T and B cells, but not with erythrocytes, granulocytes or platelets. Further examinations showed 10/11 leukemic patient cell types were positive with 1A6. In contrast, many leukemia-lymphoma cell lines were negative (14/17), i.e. T and B leukemia lymphoma cell lines, non-T and non-B leukemia cell lines as examined by complement mediated cytotoxicity test and immunofluorescence test. Other prominent characteristics of 1A6 MAB have been demonstrated, which include inhibition of myeloid colony formation (CFU-C) and suppression of human natural killer cell cytotoxicity (NKCC). These results suggest that 1A6 is a common marker for normal T, B, NK cells and leukemic patients cells having T and B cell origin, but 1A6 antigen is not expressed on many leukemia lymphoma cell lines. Therefore, it could be useful for studying malignant transformation of lymphoid cells.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Togashi H,Ghoneum M,Takasugi M,Kasai K,Mugishima H,Billing R,Terasaki PI

doi

10.1002/hon.2900070306

subject

Has Abstract

pub_date

1989-05-01 00:00:00

pages

233-42

issue

3

eissn

0278-0232

issn

1099-1069

journal_volume

7

pub_type

杂志文章
  • No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

    abstract::This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2091

    authors: Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

    更新日期:2014-06-01 00:00:00

  • Treatment of acute lymphoblastic leukemia in adults.

    abstract::Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030107

    authors: Barbui T,Bassan R,Chisesi T,Battista R,Cortelazzo S,Rodeghiero F,Capnist G,D'Emilio A,Viero P,Dini E

    更新日期:1985-01-01 00:00:00

  • Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

    abstract::Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2127

    authors: Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

    更新日期:2015-03-01 00:00:00

  • Absent clinical effects of retinoic acid and isoretinoin treatment in the myelodysplastic syndrome.

    abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070407

    authors: Hast R,Axdorph S,Laurén L,Reizenstein P

    更新日期:1989-07-01 00:00:00

  • Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.

    abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120304

    authors: Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

    更新日期:1994-05-01 00:00:00

  • Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

    abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1017

    authors: Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

    更新日期:2012-09-01 00:00:00

  • A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT

    abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2786

    authors: Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

    更新日期:2020-12-01 00:00:00

  • Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.

    abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030106

    authors: Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

    更新日期:1985-01-01 00:00:00

  • Comparison of 60 and 80 mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia.

    abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2236

    authors: Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

    更新日期:2017-03-01 00:00:00

  • Low-dose radiotherapy in diffuse large B-cell lymphoma.

    abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2368

    authors: Furlan C,Canzonieri V,Spina M,Michieli M,Ermacora A,Maestro R,Piccinin S,Bomben R,Dal Bo M,Trovo M,Gattei V,Tirelli U,Franchin G,Bulian P

    更新日期:2017-12-01 00:00:00

  • T-cell acute lymphoblastic leukaemia after liver transplantation: post-transplant lymphoproliferative disorder or coincidental de novo leukaemia?

    abstract::Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2016

    authors: Fang Y,Pinkney KA,Lee JC,Gindin T,Weiner MA,Alobeid B,Bhagat G

    更新日期:2013-03-01 00:00:00

  • Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders.

    abstract::Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2493

    authors: Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

    更新日期:2018-04-01 00:00:00

  • The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

    abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.780

    authors: Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

    更新日期:2006-09-01 00:00:00

  • BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.

    abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2344

    authors: Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

    更新日期:2017-12-01 00:00:00

  • Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.

    abstract::We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/hon.2900090411

    authors: Herbrecht R,Ortiz S,Damonte JC,Liu KL,Maloisel F,Dufour P,Bergerat JP,Oberling F

    更新日期:1991-07-01 00:00:00

  • Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

    abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.991

    authors: Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

    更新日期:2011-12-01 00:00:00

  • Intensive retreatment of adults and children with acute lymphoblastic leukemia.

    abstract::Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100206

    authors: Bassan R,Cornelli PE,Battista R,Terzi F,Buelli M,Rambaldi A,Viero P,D'Emilio A,Dini E,Barbui T

    更新日期:1992-03-01 00:00:00

  • Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program.

    abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2547

    authors: Peña C,Russo M,Martinez V,Cabrera ME

    更新日期:2019-02-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells.

    abstract::To clarify the origin of Hodgkin (H) and Sternberg-Reed (SR) cells, frozen sections of lymph nodes from 30 patients with Hodgkin's disease were immunostained with a large panel of monoclonal antibodies reactive with cells of lymphoid tissue and granulopoiesis. The results showed that: (a) H and SR cells are devoid of ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900010105

    authors: Stein H,Gerdes J,Schwab U,Lemke H,Diehl V,Mason DY,Bartels H,Ziegler A

    更新日期:1983-01-01 00:00:00

  • Glucose-6-phosphatase activity of Reed-Sternberg and Hodgkin cells.

    abstract::The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900040403

    authors: Pangalis GA,Tsavaris NB

    更新日期:1986-10-01 00:00:00

  • Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.

    abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2520

    authors: Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

    更新日期:2018-10-01 00:00:00

  • First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.

    abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.822

    authors: Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

    更新日期:2007-09-01 00:00:00

  • Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.

    abstract::Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.858

    authors: Rodríguez J,Conde E,Gutiérrez A,García JC,Lahuerta JJ,Varela MR,Pérez C,Albo C,Caballero MD

    更新日期:2008-09-01 00:00:00

  • The burden of autoimmunity in myelodysplastic syndromes.

    abstract::The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2423

    authors: Fozza C

    更新日期:2018-02-01 00:00:00

  • Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.

    abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2711

    authors: Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

    更新日期:2020-08-01 00:00:00

  • COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.

    abstract::One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900110106

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

    更新日期:1993-01-01 00:00:00

  • Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

    abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2515

    authors: Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

    更新日期:2018-10-01 00:00:00

  • Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology.

    abstract::B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.859

    authors: Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

    更新日期:2008-12-01 00:00:00

  • ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.

    abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.714

    authors: Abbott BL

    更新日期:2003-09-01 00:00:00